Appendage Management Market - Forecast(2024 - 2030)

Appendage Management Market Overview

Appendage Management Market size is estimated to reach $321.4 million by 2027, growing at a CAGR of 6.4% during the forecast period 2022-2027. Appendage management procedures are one-time procedures and have a great success rate. The complexities linked with the surgical process of appendage management have been considerably decreased post-product authorizations. The only unsuccessful surgeries are incomplete or not attempted procedures. Therefore, there are very less, if any complexities linked with the surgical procedure. Patients with atrial fibrillation who are at a heightened hazard for stroke, but who are not good long-term candidates for oral anticoagulation, may acquire an advantage from left atrial appendage (LAA) occlusion. Prothrombin time (PT) is one of the numerous blood tests periodically utilized in clinical practice to assess the coagulation status of patients and relates to Appendage Management. Atrial fibrillation (AF) is the most typical cardiac arrhythmia across the planet. Direct oral anticoagulants are secure, controllable, and offer accelerated outset of oral anticoagulation. They are a vital substitute to heparin/warfarin from all points of view, with a significant decrease in bleedings and a boost in the security and quality of life of patients. Investigations demonstrate that a left atrial appendage closure device, together with an everyday aspirin, provides a survival rate comparable to blood thinners.

The surging acceptance of closure devices owing to their success rates and the increasing prevalence of atrial fibrillation is set to drive the Appendage Management Market. The expanding government initiatives to increase public awareness pertaining to cardiovascular diseases are set to propel the growth of the Appendage Management Market during the forecast period 2022-2027. This represents the Appendage Management Industry Outlook.

Report Coverage

The report: “Appendage Management Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Appendage Management Market.

By Product Type: Epicardial LAA Closure Devices, Endocardial LAA Closure Devices.
By End User: Hospitals, Ambulatory Surgical Centers, Cardiac Centers, Others.
By Geography: North America (U.S, Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia, Rest of South America), and Rest Of The World (Middle East, Africa).

Key Takeaways

Appendage Management Market: Market Share (%) by Region, 2021

For more details on this report - Request for Sample

Appendage Management Market Segment Analysis – By Product Type:

The Appendage Management Market based on product type can be further segmented into Epicardial LAA Closure Devices and Endocardial LAA Closure Devices. The Epicardial LAA Closure Devices Segment held the largest market share in 2021. This growth is owing to the boost in security and functional efficiency of these devices. Epicardial left atrial appendage AtriClip occlusion decreases the occurrence of stroke in patients with atrial fibrillation enduring cardiac surgery. The possible benefits of Epicardial LAA occlusion over endocardial devices like no foreign body remaining in the heart are further propelling the growth of the Epicardial LAA Closure Devices segment.

Furthermore, the Epicardial LAA Closure Devices segment is estimated to grow with the fastest CAGR of 7.3% during the forecast period 2022-2027 owing to the surging investigations indicating that thoracoscopic epicardial closure of the LAA with the AtriClip PRO2 device is a possibly secure and effective treatment for stroke avoidance in patients with nonvalvular atrial fibrillation (NVAF) contraindicated for anticoagulant therapy or APT.

Appendage Management Market Segment Analysis – By Application:

The Appendage Management Market based on end-user can be further segmented into Hospitals, Ambulatory Surgical Centers, Cardiac Centers, and Others. The Hospitals segment held the largest market share in 2021. This growth is owing to the existence of skilled medical professionals like expert cardiologists in hospitals who utilize progressive Left Atrial Appendage (LAA0 closure devices to treat atrial fibrillation. The surging count of patients requiring surgeries is further propelling the growth of this segment.

Furthermore, the Cardiac Centers segment is estimated to grow with the fastest CAGR of 7.7% during the forecast period 2022-2027 owing to the soaring special and exclusive healthcare services offered to patients who are diagnosed with cardiac ailments like atrial fibrillation in conjunction with particular advantages of cardiac rehabilitation offered to senior citizens, inclusive of decreased mortality and morbidity, enhanced exercise capacity, quality of life, symptoms, and mood.

Appendage Management Market Segment Analysis – By Geography:

The Appendage Management Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America (Appendage Management Market) held the largest share with 39% of the overall market in 2021. The growth of this region is owing to the expanding pervasiveness of atrial fibrillation in the North American region. The surging technological innovation in left atrial appendage devices is further propelling the growth of the Appendage Management Market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the increasing prevalence of atrial fibrillation among the elderly in the Asia-Pacific region. The proliferating technological advancement is further fuelling the progress of the Appendage Management Market in the Asia-Pacific region.

Appendage Management Market Drivers

Increasing Predominance Of Atrial Fibrillation Is Projected To Drive The Growth Of Appendage Management Market:

As per Centers For Disease Control And Prevention (CDC), atrial fibrillation, frequently termed AFib or AF, is the most typical kind of treated heart arrhythmia and arrhythmia is when the heart thumps too haltingly, too quickly, or in a random manner. When a person has AFib, the usual thumping in the upper chambers of the heart (the two atria) is random, and blood does not move as well as it should from the atria to the lower chambers of the heart (the two ventricles). AFib may occur in short episodes, or it may be a long-lasting condition. Furthermore, as per updates by the CDC, it is assessed that 12.1 million people in the U.S. will have AFib in 2030, and in 2019 AFib was indicated on 183,321 death certificates and was the fundamental cause of demise in 26,535 of those demises. Investigation of pertinent articles has revealed that excision and exclusion of the left atrial appendage are secure and as efficient as medical handling of atrial fibrillation for stroke avoidance. The increasing predominance of atrial fibrillation is therefore fueling the growth of the Appendage Management Market during the forecast period 2022-2027.

Surging Innovative Efforts Pertaining To Left Atrial Appendage Management Are Expected To Boost The Demand Of Appendage Management:

Stroke persists as the most disastrous complexity in patients with atrial fibrillation (AF). Undoubtedly, the stroke rate for these patients is 5% per year, and 35% of patients with AF will endure a stroke over the duration of their lifetime. The left atrial appendage (LAA) is recognized to be the source of over 90% of cardiac thromboemboli and stroke, and thus, it has evolved into the focus for primary stroke avoidance in patients with AF. In the absence of perpetually efficient anti-arrhythmic medications, medical therapy has circled around the application of oral anticoagulants, stabilizing the hazard between catastrophic bleeding and thromboembolism to reduce stroke, not to mention the negative impact on quality of life. Furthermore, several techniques have been explained to mechanically exclude the LAA in patients with atrial fibrillation. Percutaneous devices like the FDA authorized Watchman (Boston Scientific, Marlborough, MA, U.S.) have displayed efficiency in decreasing stroke in AF. The surgical exclusion of the LAA has been demonstrated to decrease both early perioperative and long-term stroke. Additionally, numerous series have discovered a survival advantage owing to LAA exclusion at the time of cardiac surgery. In a meta-analysis by Tsai, there was a considerable survival benefit in patients who had a surgically excluded LAA even without an ablation procedure in comparison with patients with AF in which the LAA was left undamaged. Surgical societies are attending to the significance of LAA exclusion with this expanding proof. The surging innovative efforts pertaining to left atrial appendage management are therefore driving the growth of the Appendage Management Market during the forecast period 2022-2027.

Appendage Management Market Challenges

Challenges Of Left Atrial Appendage Management Are Hampering The Growth Of The Appendage Management Market:

There are binding government rules and regulations pertaining to the authorization of different devices which are limiting the growth of the market. Pertaining to trends in anticoagulation for atrial fibrillation (AF) in the U.S. involving an investigation of the National Ambulatory Medical Care Survey Database, in the time period of 1994 to 2003, nearly 40.5 million AF patient visits happened. Of these patients, 18.0 million (45.6%) accepted anticoagulant therapy. Amidst all patients with AF, age and application of “rate control” agents were related to accepting anticoagulant therapy. A greater magnitude of patients aged 60 years or older accepted anticoagulant therapy in comparison with patients aged 18 to 59 years. Anticoagulant therapy for patients with Atrial Fibrillation (AF) has proven advantageous and is greatly suggested, but it is challenging for numerous patients to keep up optimal treatment. Surgery is the most cost-effective alternative. Surgical techniques involve simple Left Atrial Appendage (LAA) resection, thoracoscopic surgery, and catheter treatment. Every process has its benefits and limitations, and numerous prospective investigations have been performed to assess different treatment techniques. In handling the LAA, dissection of the LAA, like alterations in its form and size owing to remodeling at the time of AF, alterations in autonomic nerve function, and thrombosis, must be comprehended anatomically and physiologically. It is thought that early treatment interference for the LAA needs to be acknowledged specifically in cases of recurrent AF. These issues are thus hampering the growth of the Appendage Management Market.

Appendage Management Industry Outlook:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Appendage Management Market. Key companies of this market are:

1. Abbott Laboratories
2. Cardia, Inc.
3. AtriCure, Inc.
4. Boston Scientific Corporation
5. Johnson & Johnson Services, Inc.
6. Medtronic Plc.
7. Occulutech International AB
8. LifeTech Scientific Co., Ltd.
9. SentreHEART (Acquired by AtriCure)

Recent Developments

Related Reports-

Left Atrial Appendage Market – Forecast (2022 - 2027)
Report Code: HCR 86331

Atrial Fibrillation Surgery Market – Forecast (2022 - 2027)
Report Code: HCR 0562

Smart Medical Devices Market - Forecast(2022 - 2027)
Report Code: HCR 30669

For more Lifesciences and Healthcare related reports, please click here